TABLE 1.
Summary of immunological and challenge results
| Treatment | Macaque | Anti-SIVsm H-4i neutralizing antibody titera | CTLs (lytic units)
|
SIVsm E660 viremiad
|
||
|---|---|---|---|---|---|---|
| SIV Gag specificb | SIV Env specificc | Peak | Post-acute phase | |||
| SIV-VRP | VW6 | 121 | 85 | 43 | 79,210 | ≤1,500 |
| PE9 | 78 | 59 | 53 | 73,130 | ≤1,500 | |
| WON | 259 | 18 | 14 | 1,899,000 | 40,726 | |
| K2F | ≤20 | 16 | 25 | 943,500 | 25,581 | |
| HA-VRP | N2P | ≤20 | NAe | NA | 42,460,500 | 44,339,026f |
| N8X | ≤20 | NA | NA | 6,539,000 | 126,093 | |
| PBS | N9K | ≤20 | NA | NA | 499,917,700 | 1,281,454 |
| W1A | ≤20 | NA | NA | 60,226,300 | 102,877,164f | |
a
On the day of challenge (Fig. 2B). The limit of detection was 20.
b
Targets were infected with vaccinia virus expressing Gag-Pro-Pol (Fig. 3).
c
Targets were infected with vaccinia virus expressing Env (Fig. 3).
d
Genome equivalents per milliliter of plasma at peak viremia (2 or 3 weeks postchallenge) or geometric mean of two measurements taken during post-acute phase (6 to 8 weeks postchallenge [Fig. 4]). The limit of detection was 1,500.
e
NA, not applicable. PBMCs from control animals could not be stimulated in vitro.
f
Early mortality from SIV-induced disease.